Mildronate (Meldonium Dihydrate)

Meldonium Dihydrate, the active ingredient in Mildronate, is a metabolic modulator presented as an injectable solution for intravenous use. It is employed to improve cardiac efficiency in patients with ischemic heart conditions and related vascular disorders.

GNH USA supplies Mildronate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mildronate acts on the cardiovascular system to address ischemic and perfusion‑related conditions.

- Ischemic heart disease: enhances myocardial energy utilization and reduces episodes of chest pain. - Angina pectoris: improves cardiac efficiency, decreasing frequency and severity of anginal attacks. - Chronic heart failure: supports ventricular function by shifting myocardial metabolism toward glucose oxidation. - Peripheral arterial disease: aids tissue perfusion and alleviates claudication symptoms.

Mildronate may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, transient. - Dizziness: especially after rapid infusion. - Injection site pain: mild discomfort at the site. - Fatigue: transient feeling of tiredness. - Elevated liver enzymes: mild, reversible.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure. - Arrhythmias: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatotoxicity: marked elevation of liver function tests. - Renal impairment: reduced kidney function. - Thrombocytopenia: low platelet count.

When considering Mildronate therapy, several safety measures are recommended.

- Renal function assessment: evaluate baseline kidney status before initiation. - Hepatic monitoring: check liver enzymes periodically during treatment. - Cardiovascular stability: ensure patient is hemodynamically stable prior to infusion. - Concomitant anti‑ischemic drugs: review for potential additive effects. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mildronate may interact with other medications affecting cardiac metabolism or hemodynamics.

Major Interactions (Avoid): - Strong CYP450 inhibitors: may increase plasma levels of Meldonium. - Potent vasodilators: risk of excessive hypotension.

Moderate Interactions (Monitor Closely): - Antiplatelet agents: monitor for bleeding tendencies. - Diuretics: watch for electrolyte disturbances. - Other metabolic modulators: assess combined effect on myocardial substrate use.